Search Results for: weber



Avery Dennison joins forces with Weber Marking on FMD solutions


Avery Dennison joins forces with Weber Marking on FMD solutions


Avery 150x66

Press Release | Avery Dennison

JUNE 19, 2018

Oegstgeest, The Netherlands: – Worldwide labeling leader Avery Dennison has entered collaboration with the labelling and coding specialist Weber Marking Systems Europe to market a new generation of pharmaceutical tamper-evident seal labelling solutions.

The move is a direct response to the impending EU Falsified Medicine Directive (FMD), joining together Avery Dennison mastery of self-adhesive materials and Weber Marking System expertise in label conversion & application.

Meeting FMD challenges

Together, the partners aim to offer the pharma industry a complete range of versatile solutions to FMD challenges in tracing, tracking and tamper-evident applications. The FMD will compel the pharma industry by Feb 9th 2019 to offer a tamper evident solution on all packaged and boxed products.

Avery Dennison has recently developed a dedicated pharma adhesive, S799P, that generates fiber tear when opening the varnished folding boxes typically used for prescription drugs, making any tampering highly visible.

Weber has already qualified S799P combined with a thin PP film face (polypropylene) on label conversion, adding specific die cuts to make the label more fragile, and on label application, where Weber has developed a dedicated tamper evident labeler that supports high speed application. The compact tamper evident labeller reliably seals up to 500 folding cartons per minute from two sides.

One-stop solutions

“Together with Weber, we can control label materials, conversion and application across our entire manufacturing and logistics chain,” commented Gabriela Gregor, Product Manager Pharmaceuticals Avery Dennison Materials Group Europe.

“Our collaboration allows us to offer pharmaceutical clients, including packaging and regulatory communities, quality and operations directors a complete one-stop shop solution,” said Ms. Gregor.

Retrofittable
Frederic Bussy, Managing Director of Weber Marking Systems, France, added: “Pharma manufacturers have to invest in solutions to comply with FMD. They are looking for a versatile solution that can be retrofitted to existing packaging lines. A self-adhesive tamper evident label offers flexibility and efficiency in manufacturing.”

“Contrary to comparable solutions in the industry, the tamper evident labeller has the great advantage that it has a very reduced footprint and can be operated from one side. As a result, it can be flexibly integrated into cramped production environments or large plants.

Furthermore, transparent labelling allows use with existing artwork and is more patient friendly,” Mr. Bussy explained.

Furthermore, Frederic Bussy advises pharmaceutical companies on the issue of aggregation. This means that the individual personalized drug packages must be packed in carton, bundle and pallet and marked individually on these higher packaging levels. The aggregation is not required under the EU regulation but it brings advantages as it facilitates logistics processes but also, for example, recalls.

About Avery Dennison

Avery Dennison (NYSE: AVY) is a global materials science and manufacturing company specializing in the design and manufacture of a wide variety of labeling and functional materials. The company’s products, which are used in nearly every major industry, include pressure-sensitive materials for labels and graphic applications; tapes and other bonding solutions for industrial, medical and retail applications; tags, labels and embellishments for apparel; and radio frequency identification (RFID) solutions serving retail apparel and other markets. Headquartered in Glendale, California, the company employs approximately 30,000 employees in more than 50 countries. Reported sales in 2017 were $6.6 billion. Learn more at www.averydennison.com.

About Weber Marking

Weber Marking Systems GmbH (Weber Marking) is the German-based leader of a group of European and international subsidiaries that specialize in developing, producing and selling highly efficient labelling and coding systems for industrial marking.

The company traces its roots back over half a century to the founding of the Weber Inc. in Chicago.

Based at Rheinbreitbach on the banks of the Rhine, south of Bonn, Weber Marking Systems was founded in 1980 as the manufacturing and development arm of Bluhm Weber Group, an international network whose core business is marking technologies.

Products include labelling and coding systems, software as well as a world-wide sales network for direct selling, service and technical support. In Germany, Weber can also provide custom and stock labels and is certified to ISO 9001:2015 quality standards.

Further information at: https://www.weber-marking.com.

Media Contact

Rob Verbruggen, Director Communications, Avery Dennison LPM
Tel: +31 650831340
Email: rob.verbruggen@eu.averydennison.com

Resources

Click on Avery Dennison collaborates with Weber Marking for more information.
Click on Avery Dennison to contact the company directly.
Click on Brand Protection to see Avery Dennison pharma solutions.
Click on Weber Labeling Machines for detailed information.


Supplier Information
Supplier: Avery Dennison
Address: Willem Einthovenstraat 11, 2342 BH Oegstgeest, The Netherlands
Tel: 31 (0) 6 15 25 04 93
Website: www.label.averydennison.eu


Gene synthesis of Artificial Genes, it’s Functional Variants and Gene Clusters


Gene synthesis of Artificial Genes, it’s Functional Variants and Gene Clusters


ATG-LOGO-300dpi-ypsb250x66

Products & Services | ATG:biosynthetics GmbH

Overview

Are you still performing complex molecular cloning work in your lab by yourself? Let‘s use a simple and increasingly popular alternate method in synthetic biology to create gene fragments, functional synthetic genes and higher order gene assemblies thereof.

ATG:biosynthetics is specialist for all types of gene sequence modulations with functional impact and can deliver these gene sequences physically as a valid alternative to PCR amplification and cloning of naturally occurring genes.

Synthetic genes are an attractive approach for those wishing to string together genes or parts of genes, potentially saving repeated rounds of amplification, restriction, ligation, selection, etc.

Scope of gene synthesis

Standard Gene synthesis covers ‘plain vanilla’ DNA sequences that have an even guanine-cytosine (GC) content ranging from 30 to 75 per cent (Figure 1) with no problematic secondary structures, extended repeats or polynucleotide stretches, etc. These ‘run-of-the mill’ genes need no sophisticated and enhanced protocols but can be synthesized with established and time-tested procedures that save time and money.

This is in contrast to complex genes that usually require significant modifications to existing protocols or completely new protocols.

Optimizing auto- and heterologous genes

Even standard genes can be optimized, either by adapting codon usage to another organism or by tweaking the original gene, e.g. by optimizing control regions, streamlining GC content, etc.

ATG’s proprietary EvoMAG (Evolution Mediated Artificial Genetics) software package provides a powerful tool for this, allowing parallel processing of multiple genes and gene variant libraries from different genetic sources. This calculates highly accessible mRNA-structures around the translational initiation regions (TIRs).

EvoMAG can be used to adapt codon use, using its smart ACDC-SD design to optimize assembly cloning, disassembly cloning and substitution design.

Codons selection for to adaptiveness with locally preferred codon use along the message as well as cut-off thresholds for codon usage, with the software set to generate a modified (normalized) usage table (Figure 2).

This offers powerful advantages including adaptability to all genetic systems and molecular approaches, easier reconstruction from ACCEPTOR to DONOR vectors and no theoretical limit in assembly of building blocks.

Resources

Click on Standard gene synthesis for more information.
Click on ATG to contact the company directly.

Figure 1: Standard gene with regular GC content: GC content fluctuates between 30 and 70 per cent.

Figure 1: Standard gene with regular GC content: GC content fluctuates between 30 and 70 per cent.

Figure 2: Adapting codon use with EvoMAG showing tabulated frequencies (blue bars) and frequency distribution (red) in the submitted sequence pre-optimization and the optimized sequence (lower image).Not all possible codons are used as a cut-off threshold for codon usage and post- optimization the frequency distribution follows the normalized table more closely.

Figure 2: Adapting codon use with EvoMAG showing tabulated frequencies (blue bars) and frequency distribution (red) in the submitted sequence pre-optimization and the optimized sequence (lower image).Not all possible codons are used as a cut-off threshold for codon usage and post- optimization the frequency distribution follows the normalized table more closely.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Bioinformatic-based synthetic gene optimization


Bioinformatic-based synthetic gene optimization


ATG-LOGO-300dpi-ypsb250x66

Products & Services | ATG:biosynthetics GmbH

Introduction

ATG:biosynthetic’s core capabilities include high-tech analytical and constructive synthetic bioinformatic-based approaches to highly parallel, multi-parametric design and optimization of single and multi-genic DNA sequences and expressed molecular libraries as well as combinatorial biodesigns.

ATG uses in silico analysis and identification of optimal promoters and enhancers to enhance in vitro experiments for the powerful, fast, effective and intelligent optimization of synthetic genes.

Synthetic gene optimization

Basic gene development consists of extracting a coding sequence, adding a promoter and terminator to it and using the resulting gene construct in expression plasmid. However evolved approaches go much further, applying advanced biocomputational calculations to optimize and streamline the expression constructs.

The bioinformatic approach is particularly necessary where promoters and other control elements from diverse organisms are incorporated into heterologous expression constructs. One example is in metabolic engineering where endogenous genes may be too weakly expressed, too tightly controlled or not exist at all.

ATG has developed in-house expertise and tools for optimization of genes, gene cassettes and entire gene clusters.

ATG’s in silico evolution-mediated artificial genetics platform, EvoMAGIS, can be used for parallel optimization of the various gene and gene cluster parameters including codon use and adaption, restriction site preferences, indices, cryptic splice sites and 5′-mRNA superstructures.

Selected parameters can be weighted over others before the sequence runs through repeated rounds of an evolutionary “tournament” that will return one or several ‘winner’ sequences.

The customer can view pre- and post-comparisons and discuss the results with ATG’s biocomputing specialists.

Constructive Biodesign

EvoMAGIS combines synthetic bioinformatics with gene cluster designs for multi-protein expression and minimal molecular function.

ATG has continuously developed the EvoMAGIS GeneIntelligence software, based on years of service and feed-back from customers. In response to their specific requirements, it has optimized constructive aspects, such as the selection and choice for suitable genetic parts and synthesis efficiency and functional aspects, including expression and solubility.

Cluster Design

Research has shown that individual genes and gene cassettes in multi-gene operons e.g. biochemical gene clusters and other assemblies can be differentially expressed thus leading to unbalanced expression of the protein products. This makes DNA cluster design and optimization extremely critical to eventual success.

Cluster design is particularly relevant in protein complexes that are sensitive to a specific stoichiometry of their component proteins.

ATG: biosynthetics are leaders in this rapidly evolving field of applied bioinformatics for Synthetic Biology.

Resources

Click on ATG:biosynthetics bioinformatic-based synthetic gene optimization for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Combined pFlexMAM Protein display system – tANCHOR


Combined pFlexMAM Protein display system – tANCHOR


ATG-LOGO-300dpi-ypsb250x66

Products & Services | ATG:biosynthetics GmbH

Overview

The latest White Paper from German-based synthetic biology, combinatorial gene design and multi-gene expression specialists ATG: biosynthetics describes how its FlexTEC mammalian expression system for trans-membrane transport of epitope and protein entities can be fused with tANCHOR protein to create the pFlexMAM protein display system. This allows fusion proteins to be predominantly displayed on the surface of mammalian (e.g. human) cells.

tANCHOR is the FlexMAM family member of vectors intended for hitchhiker fusion protein membrane transport translocations as well as anchored protein display on the cellular surfaces.

The paper shows how the combination of tANCHOR with FlexTEC Expression Technology Platform can provide ways for synthetic genes to express one to multiple genetic units in one construct.

Abstract Summary


The White Paper describes the mechanism of action of trans-membrane transport of epitope and protein entities fused with the tANCHOR protein, showing how fusions proteins created this way, such as tANCHOR-mCherry fluorescence reporter protein are predominantly displayed on the cell surface.

It shows potential application of tANCHOR for the systemic immunization by vaccines, in which epitopes are presented on the surface of a carrier protein inducing the production of antibodies which are directed against the epitopes displayed and how use of tANCHOR can allow display of transfected complete autologous cells or just its membrane fractions.

It also describes a direct DNA – immunization approach in which tANCHOR vector is tranfected into muscle tissue via a GeneGun as an example of personalized medicine approaches preventing aseptic inflammatory reactions.

A further example of extraordinary interest is using tANCHOR directly for antibody testing where the relevant epitopes are exposed directly on the cell surface; an experimental setup that can be performed in a 96-well liquid handling format with cells seeded, grown and transiently transfected with antigenic determinants like antigens and epitopes encoded by synthetic gene constructs.

Figures in the White Paper illustrate basic mechanisms of action, the range of translocation, selection, transfer and maintenance combinations, the range of available tANCHOR/FlexTEC vectors and the range of pre-determined Restriction Sites in the basic BioDesign of pFlexMAM.

To learn more about ATG:biosynthetics’ Combined pFlexMAM Protein display system – tANCHOR, please click on the brochure below:

DOWNLOAD BROCHURE

DOWNLOAD BROCHURE

About ATG: biosynthetics


Advanced Technical Genetomics: biosynthetics GmbH (ATG) is a German-based company that specializes in analytical and functional comparative genomics, molecular biology, immunology and synthetic biology services, systems and applications.

Proper gene functions are the predominant focus of ATG’s activities in the bioinformatics of constructional biology, creating maximum functional impact in design and optimization for its customers.

Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

Resources

Click on Combined pFlexMAM Protein display system – tANCHOR for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG’s molecular BioDesign Services are based on genome mining, analytics and rationally derived gene statistics


ATG’s molecular BioDesign Services are based on genome mining, analytics and rationally derived gene statistics


ATGLogo250x66

Products & Services | ATG:biosynthetics GmbH

Overview

The genomic informational space that contains the accumulated treasure of 3.5 billion years of life form evolution. This forms a huge and highly complex world with many virtual continents still to be discovered.

Primary comparative genomic data provide the keys for exploring and exploiting this world through ‘genome mining’ – bioinformatics research in genomic data. This can unearth valuable and precise formal-functional information to exploit this information in vitro as well as in combination with constructive molecular biodesigns in vivo.

Comparative genomic analyses combine newly gained evolutionary information with thorough genome statistics for identifying pattern of analytically meaningful genetic diversity and experimentally and constructively exploitable formal functionality.

ATG:biosynthetics offers advanced molecular analytics and biodesign services as well as its realization through gene synthesis based on rational genomic data by exploiting its proprietary platform technology EvoMAGIS2.0 .

Using genome statistical data for functional gene design and realization by gene synthesis

Pan-genetic and Pan-genomic data, the exploration of favorable gene functions like enzymatic activities encoded by individual single genes, can be efficiently performed, enabling the creation of gene clusters that form functional pathways coding for enzymatic cascades like physiologically active compounds (e.g. PKS/ NRPS).

The data also yields valuable information about the molecular parameters influencing functional expression of target genes, which can be delineated from genomes using comparative gen(om)e statistics RNA seq and proteomics analyses.

Genomic primary data in combination with pan-genome mining can provide excellent informational sources for rational molecular designs to drive forward development of bio-analytical technologies and bio-production processes.

Desired synthetic biological applications can thus be programmed that closely match the rationally determined formal-functional requirements of an expression target organism.

Example 1: Epitope signal hits of Mycoplasmal surfome derived peptides arranged in high density peptide array immune analytics by use of serum of infected animal's in life vaccine development.

Example 1: Epitope signal hits of Mycoplasmal surfome derived peptides arranged in high density peptide array immune analytics by use of serum of infected animal’s in life vaccine development.

Bioinformatic analysis for vaccine development

ATG is directly involved in the highest scoring EU Synthetic Biology project MycoSynVac started in 2015. The final objective of MycoSynVac is the generation of life vaccines against veterinary Mycoplasmal pathogens which are self-growing for simple, easy and cost-effective bio-production.

The combination of thorough comparative genomic analytical efforts and finally the generation of molecular constructions for displaying antigenic determinants on the surface was the task of ATG, realized in collaboration with its MycoSynVac project partners. The bacterial chassis for this purpose is under substantial genetically modification (in terms of safety and security issues of its deployment).

In addition, ATG provides computational tools for the analysis of molecular data, database developments for molecular and experimental data integration, stratifying and evaluating results for the generation of valuable information.

As well as providing life vaccine development targets, epitopes are also good for monoclonals and the design of specifically and selectively targeting and binding peptides.

Example 2:  Course of relative codon index values along a bacterial gene sequence. In red: mid to low frequency codons, in blue: higher to high frequency codons (upper image) pre codon calculations (lower image) after codon calculations

Example 2: Course of relative codon index values along a bacterial gene sequence. In red: mid to low frequency codons, in blue: higher to high frequency codons (upper image) pre codon calculations (lower image) after codon calculations

Biochemical pathway engineering

For some years, ATG has been involved in biochemical pathway engineering efforts partly in funded projects in collaboration with the Helmholtz-Institute for Pharmaceutical Research (HIPS) in Saarbrücken, Germany.

Initially these projects have been highly informative in imprinting for ATG’s in-house research and software developments. The projects have used comparative source genome analytics of a variety of different biochemical gene clusters of genes integrated in PKS/NRPS pathways. Thoroughly analyzed gene statistics, sequence compositions, distance parameters, secondary structural data (mRNA, protein), sequence motive, codon usage, ribosomal kinetics and other data are used to back-translate the protein. This allows biochemical gene clusters to be recalculated and modulated to fit the most rational target organism molecular requirements.

ATG has developed the algorithms for pathway engineering for a variety aiming on the bioproduction of different molecules like epothilone, argyrin, myxochromides, PUFAs and many more.

Resources

Click on ATG Molecular BioDesign Services for Gene Syntheses for more information.
Click on ATG to contact the company directly.
Click on Cluster Design for more information on design criteria and parameters.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG presents computational biology tools at MoDiPro workshop


ATG presents computational biology tools at MoDiPro workshop


ATG-LOGO-300dpi-ypsb250x66

Press Release | ATG:biosynthetics GmbH

APRIL 24, 2018

Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) will present it leading-edge computational biology tools at the upcoming workshop “Biotechnology Meets IT”.

The event is hosted by the ZIM Collaboration Network as part of the “Models for Diagnostics and Process Optimization” (MoDiPro) project of which ATG is a leading member.

Delegates will include biotechnology research professionals from industry and academia, seeking to optimize their processes through digitization or their collected data, e.g. for research & development, scale-up, production optimization or diagnostics.

Computational biology leaders

ATG: biosynthetics will be presenting its latest contributions in data acquisition & collection, data structuring & stratification and data reduction & integration.

“In all these fields, ATG is at the frontiers of computational biology in preclinical research and veterinary sciences,” said ATG’s CEO, Dr. Hubert S. Bernauer.

We will be showing how our use of molecular and serological experimental and clinical data sets can enable improved decision-making processes aiming on best candidates in terms of highest plausibility of target efficacy and less side effects of vaccines and drugs,” said Dr. Bernauer.

Developing diagnostic tools

The German-language workshop aims to build and strengthen contacts between biotechnology and the IT industry, focusing on starting points for projects concerned with optimization of biotechnological development and production processes for the development of prognosis tools for diagnostics. It will feature invited experts who will provide insights into the added value of data analysis methods and predictive computer models.

The workshop is staged as an all-day event on April 26, 2018, at 9:30 am at the Am Klopferspitz building in Martinsried, home of the Ellipse 1 Innovation and founding center for biotechnology. It is organized by Industrial Biotechnology Bayern Netzwerk GmbH, as network manager of the MoDiPro ZIM cooperation network.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About MoDiPro

The MoDiPro (“Models for diagnostics and process optimization”) initiative is an alliance of nine technologically advanced companies and organizations with different fields of expertise in applying advanced technologies, big data and computer-supported modeling to develop more individualized medicine.

The alliance aims to develop 21st century products such as diagnostic and decision-supporting digital tools for physicians or clever sensor-control-modules that optimize industrial production processes in real-time.

The strategic focus of the “MoDiPro” cooperation network is the digitization of biotechnology with the two main fields of application being Industrial Biotechnology, sustainable economy and individualized medical technology.

The network partners aim to harness methodologically advanced modeling and prognoses to make biotechnological processes more efficient and enable optimized and fast decisions in medicine. Products targeted are software solutions and hardware components as well as services based on the predictive power of computer models.

The network framework is provided by the Industrielle Biotechnologie Bayern Netzwerk GmbH (IBB Netzwerk GmbH), which is a network and service organization in the field of Industrial Biotechnology and sustainable economy. More information at: http://www.ibbnetzwerk-gmbh.com/en/service/pressebereich/.

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG at Biotechnology Meets IT workshop for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG returns to Berlin Life Sciences Conference with new antimicrobial technologies


ATG returns to Berlin Life Sciences Conference with new antimicrobial technologies


ATGLogo250x66

Press Release | ATG:biosynthetics GmbH

MARCH 01, 2018

Merzhausen, Germany: – German-based biotechnological company and research organization ATG:biosynthetics (ATG) is returning to the Berlin Conference on Life Sciences as it focuses on novel antimicrobial technologies.

ATG’s CEO. Dr. Hubert S. Bernauer, will again represent the company at the conference, now in its eleventh year.

Expertise in vaccine biodesign

This year’s Berlin conference, being held at the Fraunhofer-Forum Berlin (Spree Palais) will focus on ‘Novel anti-microbials and AMR Diagnostics’.

These are fields in which ATG:biosynthetics is a European leader with its expertise in bioinformatics, synthetic biology, gene and pathway design, library and expression vector design/synthesis. ATG’s novel epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology.

PepID algorithms – surfome mapping for “ONE look ALL B-cell epitopes,” identification

ATG’s strong PepID’s computational algorithms in genomic bioinformatics allow it to generate relevance. Selected deterministic PepIDIS in silico peptide libraries are realized on “high density peptide micro arrays” for screening purposes. For in vivo studies in life vaccines DNA-encoded PepIDEBP sub-libraries can then be expressed for antibody recognition, either by colony immunoblotting or using cell surface display and FACS. The new methodology aims on maximizing the efficacy of multi-epitope vaccines.

“I am looking forward to returning to this great event,” said Dr. Bernauer.

“The Berlin Life Sciences Conference gives us a great opportunity to meet some of the most eminent colleagues in the antimicrobial field,” he continued.

“It is also a rich source of industry-leading thought and perspectives, where we can gather new inspiration for our future avenues of research and business development in antimicrobial drug design,” Dr. Bernauer added.

About ATG: biosynthetics


Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About Berlin Conference on Life Sciences

Over its eleven-year history, the Berlin Conference on Life Sciences has become a highly respected annual event for Life Science decision makers, business developers, investors and legal experts.

The 11th Berlin Conference on Life Sciences is a one-day event on March 2, 2018, held at the Fraunhofer-Forum alongside the River Spree.

The 2018 event theme is the exciting market for the development of novel antimicrobials and AMR diagnostics.

Conference sessions include an industry overview, R&D trends and technology perspectives on new approaches to combating antimicrobial resistance, promising molecular methods of detecting multiple drug resistance and a legal perspective on the challenges of bringing antimicrobials to the market.

The event is organized by Biocom AG, with more information at: http://berlin-conferences.com/home/.

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG at Berlin Life Sciences Conference 2018 for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG Molecular BioDesign Services for Gene Syntheses with Effects on Different Molecular Levels


ATG Molecular BioDesign Services for Gene Syntheses with Effects on Different Molecular Levels


ATGLogo250x66

Products & Services | ATG:biosynthetics GmbH

Overview

ATG:biosynthetics (ATG) offers advanced molecular biodesign services that exploit its proprietary platform technology and its realization through DNA / gene synthesis.

Comparative genome mining describes the exploitation of the precise formal-functional information of genomes for in vitro applications combined with the in vivo deployment of constructive molecular biodesigns like for gene or immune therapies.

Computational analytical research in comparative genomics in combination with next-generation sequencing (NGS) of multiple genomes is highly informative for gaining precise formal-functional molecular information for pharmaco-medical approaches. It is moreover the key for exploring and exploiting many different aspects of the huge and extremely complex genomic informational space that contains the accumulated treasure of 3.5 Bn years of evolution, with many virtual continents still to be explored. Genome mining combined with constructive bioinformatics provides a source for rational molecular designs that can drive forward development of bioanalytical technologies, therapies and processes.

Many applications in diverse fields of life sciences can profit from comparative genomics like immune genomic (immunomics) and immune-genetics based biodesigns for vaccine design and passive immune therapies.

Immune applications like vaccine developments, mAb and other bioproduction and small molecule production in antibiotics, gene therapy applications, etc. can especially profit from the experiences of ATG gained during the last years. Crucially, the success comparative genomics is heavily dependent on the robustness of data and rigor of analysis. In bioinformatics, ATG is dedicated to delivering the highest levels of quality.

Genome mining through bioinformatics

Progressive development of the comparative and functional genomics analyses defines the basis of ATG’s advanced core bioinformatics expertise.

Using the analogy of a microscope, ATG claims that the precision of genomic analyses relates especially to the resolution of because magnification needs high resolution for not to provide no empty results. This prerequisite is bringing into view molecular information that was not previously visible. Crucially, most detailed analyses and its assessment has increased the quality of inputs into bioinformatics computations, opening the way for more valuable outputs.

One of ATG’s main focus is on bioinformatics that enable the in silico exploration of genomes in combination with experimental proof to provide customers with the best synthetic genes or coding (minimal) parts of it (e.g. epitopes) for potentially unlimited different applications in molecular sciences and synthetic biology.

ATG:biosynthetics is involved in the biodesigns of highest density micro-arrays with up to 70.000 different highly selected chemical peptides but also in more focused deterministic expressible biopeptides in Pro- and in Eukaryotes, such as the mammalian display system tANCHOR.

Deterministic biopeptide libraries are expressed for display in both, prokaryotes and eukaryotes, for this end ATG provides e.g. the mammalian display system tANCHOR. In combination with phage display this protein display systems can lead to mAB-developments in highest sophistication.

ATG is directly involved in the highest scoring EU Synthetic Biology project “MycoSynVac” with responsibility for the comparative genomics identifying accessible protein structures on the surface of bacteria that serve as target epitopes for immune therapies like life vaccines and for immune therapies by monoclonals and the design of specifically and selectively targeting and binding peptides.

ATG uses genomic analyses also in a gene function oriented fashion by selecting and extracting genes exclusively coding for proteins located on the surface of e.g. bacteria and in addition pre-selected for the functional domains outside of the cellular surface, designing high density micro arrays for analyzing polyclonal sera. The ATG high density microarray biodesign approach, has proved its validity by identifying more than 95 percent of the known antigens by using polyclonal sera,. Target epitopes were designed to be derived from a variety of different available genomes exhibiting minimum redundancy with more than 60 percent of specific binders identified peptides detected by antibodies form sera representing new potential epitopes.

ATG gene synthesis services – Final Realization of Molecular Biodesigns

ATG is dedicated to providing all types of molecular specifications from small peptide libraries, expressed biopeptide genes to highly integrated molecular entities like many small molecule biochemical pathways, gene clusters of signaling pathways, hetero-protein complexes, combinatorial sequence biodesigns (vectors, genes, other specifications) and especially we are focused on providing to you the best bioinformatics for your intended functional biodesign.

Resources

Click on ATG Molecular BioDesign Services for Gene Syntheses for more information.
Click on ATG to contact the company directly.

Figure-1: Workflow for biodesign, bioengineering and refactoring for the realization of biochemical gene clusters, heteroprotein complexes or signalling pathways and many more. The planning phase of a functional biodesign is of highest importance and priority. From the very beginning these projects are starting best with explorative genome analyses in silico, e.g. for the identification and characterization of new natural pathways for specific classes of natural compounds a customer company might be interested in. The genome of a target organism combined with  research in literature also can give highly valuable information about the requirements of regulatory sequences and functional building blocks to be be used. Of highest importance are the codon bias determining the ribosomal kinetics of genes. After this phase the iterative refactoring of natural pathways  towards it‘s in vivo activation or the expression improvement in the homologous or a heterologous host can start and the the biodesign can be relized.

Figure-1: Workflow for biodesign, bioengineering and refactoring for the realization of biochemical gene clusters, heteroprotein complexes or signalling pathways and many more. The planning phase of a functional biodesign is of highest importance and priority. From the very beginning these projects are starting best with explorative genome analyses in silico, e.g. for the identification and characterization of new natural pathways for specific classes of natural compounds a customer company might be interested in. The genome of a target organism combined with research in literature also can give highly valuable information about the requirements of regulatory sequences and functional building blocks to be be used. Of highest importance are the codon bias determining the ribosomal kinetics of genes. After this phase the iterative refactoring of natural pathways towards it‘s in vivo activation or the expression improvement in the homologous or a heterologous host can start and the the biodesign can be relized


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG joins MoDiPro data application project


ATG joins MoDiPro data application project


ATGLogo250x66

Press Release | ATG:biosynthetics GmbH

DECEMBER 20, 2017

Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) has joined the collaborative project MoDiPro managed by IBB Netzwerk that aims to harness complex data management to develop superior medical outcomes.

The MoDiPro (“Models for diagnostics and process optimization”) initiative has attracted German Federal Government funding under the BMWi ZIM (Central Innovation Programme for SMEs) program. It is currently an alliance of nine technologically advanced companies and organizations with different fields of expertise in applying advanced technologies, big data and computer-supported modeling to develop more individualized medicine.

The alliance aims to develop 21st century products such as diagnostic and decision-supporting digital tools for physicians or clever sensor-control-modules that optimize industrial production processes in real-time.

Bioinformatic leadership

ATG is already a leader in the field of applied IT with its expertise in bioinformatics, synthetic biology, gene and pathway design and engineering, library and expression vector design/synthesis and its novel Epitope mapping service that combines computational analysis of pathogen surfome genes with PepID biopeptides expression and micro array expression technology.

ATG’s strong PepID’s computational algorithms allow it to generate overlapping deterministic DNA-encoded peptide libraries from multiple pathogen genomes. The peptide sequences generated are non-redundant and restricted only for the accessible parts of surface proteins. This can be achieved by analysing protein structural data. Screening arrays and focussed expressed biopeptides can then be subjected to poly- and monoclonal antibodies recognition in many different assays. ATG’s tANCHOR mammalian cell surface display is one possible way to expose epitopes in vitro as well as in vivo, e.g. in autologous environments. The new methodology can be used to maximize the efficacy of multi-epitope vaccines in personalized medicine.

Applied data modeling

ATG’s CEO, Dr. Hubert S. Bernauer, commented:

“Collaborating with the IBB Netzwerk as part of the MoDiPro program provides us with a great platform from which to extend our activities and apply our advanced bioinformatics and algorithms on new types of medical data mining and experiment data integration technologies.”

“We see real opportunities within MoDiPro to apply our expertise in application of data modeling to develop a new generation of solutions that are closer to the end-user and individual patient” said Dr. Bernauer.

Adding value

IBB Netzwerk Managing Director Prof. Haralabos Zorbas said the network could add value to the activities of all of its members.

“Cooperation networks provide a highly fertile ground for implementing innovative ideas more efficiently and economically in R&D projects and for realizing market-ready products and processes,” said Prof. Zorbas.

“We support our member in acquiring further, suitable project partners as well as in initiating and elaborating R&D proposals. We can also strengthen links with potential large-scale pharmaceutical companies and end users, such as clinics and patient organizations,” he added.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About MoDiPro

The strategic focus of the “MoDiPro” cooperation network is the digitization of biotechnology with the two main fields of application being Industrial Biotechnology, sustainable economy and individualized medical technology.

The network partners aim to harness methodologically advanced modeling and prognoses to make biotechnological processes more efficient and enable optimized and fast decisions in medicine. Products targeted are software solutions and hardware components as well as services based on the predictive power of computer models.

The cooperation network “MoDiPro” is funded by the German Federal Ministry for Economic Affairs and Energy within its Central Innovation Program for SMEs.

The funding for Phase 1 runs from June 2017 to May 2018, after that a continuation in phase 2 will be pursued.

The network framework is provided by the Industrielle Biotechnologie Bayern Netzwerk GmbH (IBB Netzwerk GmbH), which is a network and service organization in the field of Industrial Biotechnology and sustainable economy.

More information at: http://www.ibbnetzwerk-gmbh.com/en/service/pressebereich/pr-28082017-modipro-phase-1/.

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG joins MoDiPro data application project for more information.
Click on ATG to contact the company directly.

m1


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG joins DiagNET consortium


ATG joins DiagNET consortium


ATG150x39

Press Release | ATG:biosynthetics GmbH

DECEMBER 11, 2017

Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) has joined the multinational DiagNET project working for joint development of new diagnostic procedures in the antimicrobial sector.

ATG’s main contribution to the DiagNET project will be its novel Epitope mapping service that combines computational analysis of pathogen genomes with PepID-biopeptides expression and high-density peptide microarray technology. This new methodology aims to improve diagnostic value by promoting unambiguous results and to maximize the efficacy of multi-epitope vaccines.

Multiresistant pathogens

DiagNET aims for “diagnostics of the future” in developing new diagnosis procedures, drawing on a competence network of industry and science that includes the four countries bordering Lake Constance: Switzerland, Germany, Austria and France.

The project is coordinated by the Konstanz-based BioLAGO e.V., regional life science network with support from the European Union via its Interreg V Alpenrhein-Bodensee-Hochrhein program.

The main topics of DiagNET’s working groups are: multiresistant pathogens, therapy monitoring, digital diagnostics and lifestyle diagnostics.

Powerful peptide libraries

ATG: biosynthetics has created an optimal set of peptide libraries for epitope mapping by developing bioinformatics prediction tools that allowed the team to use in silico techniques to reduce the number of peptides to test.

When combined with powerful PepID computational algorithms, these technologies allow ATG to generate deterministic DNA-encoded peptide libraries that can then be expressed on antibody recognition, either by colony immunoblotting or using cell surface display.

Speeding diagnostic development

“We have much to contribute to advanced diagnostics“ said ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, who played a leading role in developing the new library design system.

“By reducing complexity, we can considerably reduce the cost and speed the development of epitope mapping that can model the entire surfome of target pathogens,” said Dr. Bernauer.

ATG initially developed its peptide library for epitope mapping to support 2013 and 2014 research projects aiming to identify origins and human antibody responses to the West Nile Virus (WNV).

Subsequently, as part of the MycoSynVac consortium, ATG has developed a new workflow that drastically reduces the number of peptides to test in compiling an optimal list.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About DiagNET

DiagNET links companies, research facilities and clinics with expertise in various diagnostic fields, including research and development, production, marketing and application.

The project “diagnostics of the future” aims to develop and apply new diagnostic procedures from a competence network of industry and science that includes the four countries bordering Lake Constance: Switzerland, Germany, Austria and France.

The project is coordinated by BioLAGO e.V., the life science network around Lake Constance, with support from the European Union via its Interreg V Alpenrhein-Bodensee-Hochrhein program.

The main topics of DiagNET’s working groups are: multiresistant pathogens, therapy monitoring, digital diagnostics and lifestyle diagnostics.

More information at: http://www.diagnet.org/en/home/.

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

OR

Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0)7423-8772786
Email: josef.maier@atg-biosynthetics.de

Resources

Click on ATG: biosynthetics joins DiagNET project for more information.
Click on ATG to contact the company directly.

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG updates progress on PepID technology at MycoSynVac annual meeting


ATG updates progress on PepID technology at MycoSynVac annual meeting


ATG150x39

Press Release | ATG:biosynthetics GmbH

NOVEMBER 09, 2017

Merzhausen, Germany: – Advanced genetomic contract research organization ATG:biosynthetics (ATG) will share progress milestones on its innovative PepID peptide immune target identification technology with MycoSynVac project partners at their upcoming annual meeting in the Netherlands.

The MycoSynVac project aims to use cutting-edge synthetic biology methodologies to engineer Mycoplasma pneumoniae as a universal chassis for vaccination.

Advanced algorithms

ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, will tell the meeting that his team has made significant progress on developing PepID’s comparative genomics computational algorithms.

These can be used to generate unique deterministic DNA-encoded peptide libraries from different genomes that can then be used for high density peptide microarray serum analytics or expressed for antibody recognition, either by colony immunoblotting or using cell surface display. The new methodology aims to maximize the efficacy of multi-epitope vaccines.

“The MycoSynVac annual meeting provides a precious opportunity to meet our project partners face to face and share insights on how our PepID technology can provide an important route to open up new insights in developing Mycoplasma pneumoniae as the basis for broad-spectrum animal vaccines,” said Dr. Bernauer.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About MycoSynVac project
The MycoSynVac Consortium unites scientists from different disciplines representing nine commercial and academic life sciences centers from around Europe to develop innovative vaccine formulation and delivery.

In particular, the project is focused on engineering Mycoplasma pneumoniae as a broad-spectrum animal vaccine. Mycoplasma is a tiny genus of bacteria that are considered pathogens in humans and animals. Their extremely small genome (as few as 580.000 base pairs compared with some three billion for human genome) combined with lack of cell wall around their cell membrane make them a particularly interesting study target.

The 2017 MycoSynVac annual meeting will take place on November 13-14 at the campus of project partner MSD Animal Health (formerly Intervet) at Boxmeer, south of Nijmegen, Netherlands, followed the next day (November 15) by a scientific symposium at nearby Radboud University.

The event is organized by Barcelona-based MycoSynVac, with more information at: http://www.mycosynvac.eu/events/vaccine-symposium-vaccines-different-levels-complexity-subunit-whole-cell-formulations.

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG at MycoSynVac Annual Meeting for more information.
Click on ATG to contact the company directly.

a1


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG brings leading edge PepID technology to Netherlands vaccines symposium


ATG brings leading edge PepID technology to Netherlands vaccines symposium


ATG150x39

Press Release | ATG:biosynthetics GmbH

NOVEMBER 06, 2017

Merzhausen, Germany: – Advanced synthetic biology company ATG:biosynthetics (ATG) will present highlights of its innovative PepID peptide epitope tagging technology to the upcoming vaccine symposium in the Netherlands.

ATG will show how its strong PepID’s computational algorithms allow it to generate deterministic DNA-encoded peptide libraries that can then be expressed for antibody recognition, either by high-density microarrays, colony immunoblotting or using cell surface display. The new methodology aims to maximize the efficacy of multi-epitope vaccines and enables the development of innovative tools for previously unmet diagnostic needs.

Antimicrobial drug design

The symposium is largely organized by the MycoSynVac project, which aims to use cutting-edge synthetic biology methodologies to engineer Mycoplasma pneumoniae as a universal chassis for vaccination.

ATG:biosynthetics will be represented at the symposium by its CEO, Dr. Hubert S. Bernauer and its CSO, Dr. Josef Maier.

“The Vaccines Symposium provides an important opportunity to network with elite researchers in our field and show how PepID technology can provide an important route to developing more effective multi-epitope vaccines,” said Dr. Bernauer.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About Mycosyncvac vaccines symposium

The 2017 Vaccine Symposium jointly hosted by the MycoSynVac Consortium together with the Radboud University at Nijmegen, Netherlands, will bring scientists from different disciplines in academia and industry to share ideas on the impact of innovative vaccine formulation and delivery.

The one-day symposium will take place on November 15 at Radboud University Medical Center in Nijmegen, The Netherlands.

The symposium will involve up to 100 delegates and will feature keynote presentations from worldwide experts together with short talks of selected participants.

The event is organized by Barcelona-based MycoSynVac, with more information at: http://www.mycosynvac.eu/events/vaccine-symposium-vaccines-different-levels-complexity-subunit-whole-cell-formulations

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG at MycoSynVac Symposium for more information.
Click on ATG to contact the company directly.

a1


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG Eukaryotic Gene Expression Modulation via BioDesign


ATG Eukaryotic Gene Expression Modulation via BioDesign


ATGLogo250x66

Products & Services | ATG:biosynthetics GmbH

Overview

ATG:biosynthetics (ATG) offers Molecular BioDesign solutions that combine the proprietary EvoMAGIS (in silico evolution mediates to artificial genomes) bioinformatics platform with the realization of genes and clusters via gene syntheses.

BioDesigned synthetic eukaryotic genes are tailored to realize sequence modulated physical DNA-sequences like single genes or multiple formal-functional gene variants for gene activity analyses and minimal functional gene fragment libraries.

Modular BioDesign can be applied to epitope screening, biochemical gene clusters and hetero-protein complex coding gene clusters, combinatorial vector designs, gene libraries and a wide range of sequence calculations up to 16 kb, according to individual customer requirements.

All these different approaches can be mutually realized to fit particular experimental and developmental needs.

Background

In contrast to functional improvements of bacterial expression Eukaryotic expression optimization procedures need to have an impact on additional molecular levels and more functional variants are to be considered.

Basic cellular transcription is characterized by the principles of general transcription of housekeeping genes, cellular differentiation and its specific promoters with selective transcription factor binding sites in the genome. The cytosolic expression machine is using differentiation reflecting codon tables with specific variant codon frequency related to the frequency of altered amino-acyl-tRNA concentration. Especially for the substantial improvement of heterologous expression many more molecular parameters especially on the mRNA level and protein level need to be considered to approach a realistic view of functional expression. Cellular traffic for localization and export of proteins as well as its glycosylation are additional features that impact on the final outcome of the correct function in terms of yield of mature vs. premature product accumulation as well as the desired maximum specific activity of the final gene products.

Modular BioDesign

ATG:biosynthetics has a strong background in comparative genomics bioinformatics, a source of valuable information to access, that is highly supportive for ATG’s BioDesigns. For functional expression parameter analyses, ATG can call on long experience in gene services and excellent proprietary bioinformatic tools to provide competitive advantage.

ATG BioDesigned synthetic genes are tailored for the realization of sequence modulated physical DNA-sequences like single genes, multiple formal-functional gene variants for gene activity analyses and minimal functional gene fragment libraries. Applications of Genomics based BioDesigns in this field are calculating high density peptide microarrays for epitope screening, biochemical gene clusters and hetero-protein complex coding gene clusters, combinatorial vector designs, gene libraries and all different kind of sequence calculations according to customer requirement specifications (up to 16 kb).

All these different approaches can be realized in a mutual realization process with the customers to meet individual experimental and developmental requirements.

Working from available genomic data

a1

ATG integrates the highest level of molecular data sets available and genomic analyses as well as the related literature. Condensing all this information provides valuable decision process relevant information about the maximum formal- functional molecular requirements. Pareto optimized sequence designs are realized by simultaneous multi-parametric sequence calculations. This allows the analysis to achieve the best functional tradeoffs between sequence requirement constraints.

Removing unwanted binding sites and sequence motifs

a2

Sequence motifs are either desired or need to be identified and eliminated in case they occur arbitrarily during the sequence modulation processes in statu nascendi. Many of the functional sequence motifs show a degenerate sequence composition, resulting in variations that can be described in base weighted libraries. Desired motifs can be introduced during the multi-parametric sequence modulation processes while modulating other sequence parameters like the codon use.

Removing unwanted mRNA structural features

a3

Smooth transcripton and translation processes are dependent on the mRNA structure but pausing signals can also be highly valuable in assuring a functional outcome. Many of these RNA bound expression relevant parameters can be analysed in detail and considered in the final design before starting any experiments.

Integrating preferred structural features

a4

Structure functional relations are in general extremely important in Protein and RNA interactions. These relations are obvious and not relative easily to understand. Its correct and functional realizations are still a formidable task which needs sophisticated tools.

Optimizing regulatory features

a5

Regulatory features are mostly determined by highly specific signal structures, even when such structures are degenerated in the sequence and mostly dependent on positional sequence context. Descriptive motif libraries are deployed for handling molecular function dependent on specific interaction with more or less specific motifs with variable activity.

Optimizing protein features

a6

There is a long list of protein features that can support the generation of an improved functional product. Correct folding of proteins has a high impact on the final functional properties of the gene products, including specific activity, transport, efficient cellular traffic, export and correct location. Local amino acid composition, slow codon pattern, protein modification pattern like glycosylation, signal structures, etc., can also have a substantial impact on the protein function.

Resources

Click on ATG Eukaryotic Gene Expression Modulation via BioDesign for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG presents epitope-mapping advance to BioValley event


ATG presents epitope-mapping advance to BioValley event


ATG Logo
MycoSync Logo
EU Logo

Press Release | ATG:biosynthetics GmbH

MARCH 09, 2017

Merzhausen, Germany: – German-based pre-clinical contract research organization ATG:biosynthetics (ATG) will use the tri-national BioValley Companies Day in late March to present its latest Epitope Mapping Service.

Dr. Adrien Eberlin, Project Manager and Lab Manager in ATG’s R&D Department will represent the company at the BioValley Freiburg event and will talk in the 1150hrs slot on ‘PepID-focused BioDesign of peptides for epitope mapping microarrays in vaccine development by genome analysis.’

The lecture describes ATG’s novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology. The new methodology aims to maximize the efficacy of multi-epitope vaccines.

Powerful PepID algorithms

The powerful PepID computational algorithms allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.

“The new workflow reduces the complexity of the library while conserving the biodiversity of the peptides,” commented ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, who played a leading role in developing the new library design system.

“Such reduction of complexity considerably reduce the cost and time of global epitope mapping project including the entire surfome of the pathogen to be targeted,” Dr. Bernauer explained.

MycoSynVac origins

ATG initially developed its peptide library for epitope mapping to support 2013 and 2014 research projects aiming to identify origins and human antibody responses to the West Nile Virus (WNV).

Subsequently, as part of the MycoSynVac consortium, ATG has developed a new workflow that drastically reduces the number of peptides to test in compiling an optimal list.

The presentation will also acknowledge the contribution of Dr. Josef Maier of Information Services to Life Science (IStLS), a long-term partner of ATG that develops bioinformatic tools for the company.

Bioinformatic prediction

When combined with powerful PepID computational algorithms, these allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.

“We believe our peers at BioValley will be very interested to hear about this powerful new research tool,” said Dr. Eberlin.

“We are now bringing epitope-mapping to market and will be communicating more intensively on this advanced ATG service during the course of 2017,” said Dr. Eberlin.

About ATG: biosynthetics

ATG :biosynthetics is a German-based pre-clinical contract research company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway engineering) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About BioValley Companies Day

BioValley Companies Day is a tri-national market place for business contacts and networking covering the life sciences industries of Germany, Switzerland and France.

The English-language event offers a unique opportunity for companies to present their best offers, innovations and opportunities to their peers, with extensive networking opportunities for discussion and face-to-face meetings.

BioValley companies Day 2017 is a one-day event held between 0900 and 1800 on March 28 at the Tagungscenter ETAGE SolarInfoCenter in Freiburg, Germany.

The event is organized by BioValley Deutschland e.V. with more information at: https://www.gesundheitsindustrie-bw.de/en/event/6-biovalley-companies-day/

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

OR

Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0)7423-8772786

Resources

Click on ATG presents epitope-mapping advance to BioValley event for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH

Epitope-mapping workflow

Epitope-mapping workflow


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG presents epitope-mapping advance to DECHEMA Peptide Symposium


ATG presents epitope-mapping advance to DECHEMA Peptide Symposium


ATG Logo
MycoSync Logo
EU Logo

Press Release | ATG:biosynthetics GmbH

MARCH 06, 2017

Merzhausen, Germany: – German-based pre-clinical contract research organization ATG:biosynthetics (ATG) will present details of its advanced new Epitope Mapping Service to the 13th DECHEMA German Peptide Symposium in Erlangen.

Dr. Adrien Eberlin, Project Manager and Lab Manager in ATG’s R&D Department will represent the company at the conference at University Clinic of Erlangen.

On Day Three of the event, Wednesday March 22, Dr. Eberlin will deliver a lecture on ‘PepID-focused BioDesign of peptides for epitope-mapping microarrays in vaccine development by genome analysis’ to the session on Peptides in Immunology.

He will describe ATG’s novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology. The new methodology aims to maximize the efficacy of multi-epitope vaccines.

MycoSynVac origins

“We believe our peers at the Peptide Symposium will be very interested to hear about this powerful new research tool,” said Dr. Eberlin.

“We are now bringing epitope-mapping to market and will be communicating more intensively on this advanced ATG service during the course of 2017,” said Dr. Eberlin.

ATG initially developed its peptide library for epitope mapping to support 2013 and 2014 research projects aiming to identify origins and human antibody responses to the West Nile Virus (WNV).

Subsequently, as part of the MycoSynVac consortium, ATG has developed a new workflow that drastically reduces the number of peptides to test in compiling an optimal list.

Bioinformatic prediction

When combined with powerful PepID computational algorithms, these allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.

The presentation will also acknowledge the contribution of Dr. Josef Maier of Information Services to Life Science (IStLS) as a co-developer of the new epitope mapping tool.

Reducing complexity

“The new workflow reduces the complexity of the library while conserving the biodiversity of the peptides,” commented ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, who played a leading role in developing the new library design system.

“Such reduction of complexity considerably reduce the cost and time of global epitope mapping project including the entire surfome of the pathogen to be targeted,” Dr. Bernauer explained.

About ATG: biosynthetics

ATG :biosynthetics is a German-based pre-clinical contract research company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway engineering) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About German Peptide Symposium 2017

The German Peptide Symposium is an annual event that covers all areas of peptide science, including peptide chemistry, biochemistry, biophysics, structural biology, immunology, pharmacology, as well as the use of proteins and peptides in medicine and material sciences.

The 13th Annual Symposium is a four-day event opening March 20 at the Friedrich-Alexander University Clinic of Erlangen, near Nuremberg in South Eastern Germany.

The event is organized by DECHEMA e.V. (Society for Chemical Engineering and Biotechnology), a non-profit professional society of almost 6,000 members.

DECHEMA brings together experts from a wide range of disciplines, institutions and generations to stimulate scientific exchange in chemical engineering, process engineering and biotechnology to represent these fields in science, industry, politics and society.

More information at: http://dechema.de/en/peptide13_2017.html

Media Contacts

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

OR

Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0)7423-8772786

Resources

Click on ATG at German Peptide Symposium for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH

Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG brings leading-edge antimicrobial technologies to Berlin Life Sciences Conference


ATG brings leading-edge antimicrobial technologies to Berlin Life Sciences Conference


ATG Logo

Press Release | ATG:biosynthetics GmbH

FEBRUARY 14, 2017

Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) will be an important presence at the 2017 Berlin Conference on Life Sciences as it focuses on novel antimicrobial technologies.

ATG is a leader in this field with its expertise in bioinformatics, synthetic biology, gene and pathway design, library and expression vector design/synthesis and its novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology.

ATG’s strong PepID’s computational algorithms allow it to generate deterministic DNA-encoded peptide libraries that can then be expressed on antibody recognition, either by colony immunoblotting or using cell surface display. The new methodology aims to maximize the efficacy of multi-epitope vaccines.

Antimicrobial drug design

The conference, now in its tenth year, is being held at the British Embassy in Berlin, where ATG will be represented by its CEO, Dr. Hubert S. Bernauer.

“The Berlin Life Sciences Conference is a highly esteemed event that gives us a great opportunity to meet other eminent colleagues in the field and establish contact with other SMEs,” said Dr. Bernauer.

“It is a also a rich source of industry-leading thought and perspectives, where we can gather new inspiration for our future avenues of research and business development in antimicrobial drug design,” Dr. Bernauer added.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About Berlin Conference on Life Sciences

Over its ten-year history, the Berlin Conference on Life Sciences has become a highly respected annual event for Life Science decision makers, business developers, investors and legal experts.

The 10th Berlin Conference on Life Sciences is a one-day event on February 24, 2017, held at the British Embassy on Berlin’s historic Wlhelmstrasse.

The upcoming conference will focus on the exciting market and challenging conditions for the development of Novel Antimicrobials. Conference sessions include an industry overview, R&D trends and a technology perspective on new approaches to efficiently combating antimicrobial resistance, discussion of the legal and regulatory environment and a Start-up Pitch that allows Investors to hear direct from innovators in the sector.

Speakers will cover the entire value chain from research & development to the market.

The event is organized by Biocom AG, with more information at: http://berlin-conferences.com/home/

Media Contact
Dr. Hubert S. Bernauer, CEO, ATG:biosynthetics GmbH
Email: info@atg-biosynthetics.de
Tel: +49 (0)761 888 9424

Resources

Click on ATG brings leading-edge antimicrobial technologies to Berlin Life Sciences Conference for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG bioinformatics brings novel epitope mapping to International HIPS Symposium


ATG bioinformatics brings novel epitope mapping to International HIPS Symposium


ATG Logo
MycoSync Logo
EU Logo

Press Release | ATG:biosynthetics GmbH

JUNE 23, 2016

Merzhausen, Germany: – German-based clinical research organization ATG:biosynthetics will be an important presence at the 6th HIPS International Symposium in Saarbrucken, sharing insights on its new Epitope mapping service.

ATG will present a poster at the conference: ‘Epitope mapping workflow for vaccine development combining computational analyses of the pathogen genome to the PepID biopeptides expression technology.’

New discovery routes

The poster, authored by ATG scientists Adrien Eberlin and Hubert Bernauer, along with Josef Maier of IStLS Information Services, demonstrates how the new epitope mapping workflow developed by ATG:biosynthetics can improve the discovery of new diagnostic and therapeutic epitopes.

“Based on available genomic data, we are attempting to integrate the highest level of molecular biodiversity to increase the scope of protection. Simultaneously we intend to reach the maximum reduction of dispensable molecular complexity in terms of redundancy as well as structural-functional considerations regarding the antigens to be analyzed,” said Dr. Eberlin.

Combining algorithms with libraries
“Our strong PepID’s computational algorithms allow us to generate rationally designed, deterministic DNA-encoded peptide libraries that can then be expressed and submitted to antibody recognition, either by colony immuno-blotting or using a surface display technology,” Dr. Bernauer added.

The new epitome mapping methodology aims to increase the specificity of researchers diagnostic tools, improving experimental significance and maximizing the efficacy of multi-epitope vaccines.

The novel mapping proposed by ATG will initially specialize in gene optimization and synthesis.

The team is now focusing on development of a veterinary vaccine against mycoplasma strains for an €8m project, undertaken under the EU’s Horizon 2020 (H2020) Research and Innovation program, that combines gene engineering and biotechnology to design new vaccines based on the bacterium Mycoplasma pneumoniae.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About International HIPS Symposium 2016

The International HIPS Symposium brings together renowned scientists and young investigators from three pharmaceutical communities: natural products, medicinal chemistry and drug delivery.

The 6th International HIPS-Symposium, ‘Recent Developments in Infection Research’ is a one-day event taking place on June 29 at the Aula building at the campus of Saarland University at Saarbrucken, Germany.

The symposium provides a forum for senior scientists to exchange ideas across borders of classical disciplines while also providing young investigators with opportunities to receive feedback on their projects from international experts in their chosen fields.

The symposium will feature speakers from eminent universities in Germany and Luxembourg as well as the European Bioinformatics Institute, along with numerous posters from scientists and researchers.

The event is organized by the Helmholtz Centre for Infection (HZI) with more information available at: https://www.helmholtz-hzi.de/en/news_events/events/view/event/info/6th_international_hips_symposium/

Media Contact

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de
OR
Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0) 7423-8772786
Email: josef.maier@istls.de

Resources

Click on ATG bioinformatics brings novel epitope mapping to International HIPS Symposium for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


PepID for Epitope mapping


PepID for Epitope mapping


ATG Logo

Products & Services | ATG:biosynthetics GmbH

Introduction

ATG:biosynthetics has developed its PepID technology to provide advantageous, straightforward workflows for epitope analyses of antigens and antigenic determinants.

PepID’s strong computational algorithms generate rationally designed, deterministic DNA-encoded peptide libraries. The system hosts and expresses these libraries using a smart bio-based vector system, generally based on proteins that come from diagnostically and epidemiologically relevant bacteria and viruses, such as flaviviruses, or even cancer antigens.

In silico, in vitro, in vivo

PepID is a bio-peptide system in which peptides are produced and surface displayed in a biological system, usually a bacterial host organism or Mammalian cells, from a plasmid DNA construct. It streamlines the identification of epitopes as well as the development of bioanalytics, diagnostics and vaccines using in vitro chemical peptides and in vivo bio-peptides.

To identify B-cell, linear or conformational, or T-cell epitopes, ATG performs global data mining and analyses the available literature data and sequences of the proteins of interest to establish optimized non-redundant sets of peptides mirroring the biodiversity of relevant potential antigens.

In a two steps procedure, the analysis system uses designs of chemical peptide microarrays covering the pool of synthetic peptides previously determined in silico to identify all potential epitopes in an in vitro pre-screening. Following this first evaluation of the level of recognition of each peptide by the serum of interest, PepID gathers desired candidates in library for further display as bio-peptides for in vivo epitope-mapping which mimic the natural context of the epitope in the cellular environment.

Epitope mapping deterministic library

PepID thus generates libraries that are deterministic as the peptide sequences are based on existing and usually well-studied proteins. Compared with chemically synthesized random libraries, PepID provides permutations of sequences that are sorted with far more biological relevance.

The PepID library feature delivers numerous advantages:

  • Reproduction of unlimited peptide candidates without any alteration.
  • High flexibility in expression through the library’s ability to use simple sub cloning to adapt tags or inducibility to fit with the project’s needs.
  • Radically reduced library size compared to random libraries with defined low complexity.
  • Elimination of irrelevant peptides or empty vectors.

Optimal workflow

PepID combines high-throughput screening potential of in vitro synthetic chemical peptides gathered in microarray with the flexibility and stringent reproducibility of in vivo bio-eptides library design. Together, these define optimal workflows for identification of new epitopes and the development of bioanalytics, diagnostics and vaccines.

Comparative genomics is an indispensible tool in project planning, fitting the functional realities of specific activities with protein expressing systems.

PepID technology can be used to perform mapping of epitopes, covering the biodiversity of pathogen bacterial and viral genomes in order to discover the most plausible antigens.

If you wish to cover specific immunologically more relevant areas more tightly, you can adjust either the peptide length or the peptide overlap as shown in Figure 2. This can help you identify new linear epitopes and possibly even conformational epitopes.

Resources

Click on PepID for Epitope mapping for more information.
Click on ATG to contact the company directly.

PepID separates hosting and expression into two subsystems. First, a protein sequence of interest is reverse translated and then partitioned into linear peptides of defined length and overlap in silico. Peptide-coding DNA sequences are then assembled into a single or a set of compact constructs to be synthesized de novo and hosted on the source / back-up vector from which they can be released whenever necessary. Peptides are released by simply cutting with a unique combination of restriction enzymes and then cloned into the expression vector. The expression vector can be uniquely tagged (e.g. GST) to produce a fusion peptide ready for expression testing and utilization.

Figure 1: PepID separates hosting and expression into two subsystems. First, a protein sequence of interest is reverse translated and then partitioned into linear peptides of defined length and overlap in silico. Peptide-coding DNA sequences are then assembled into a single or a set of compact constructs to be synthesized de novo and hosted on the source / back-up vector from which they can be released whenever necessary.
Peptides are released by simply cutting with a unique combination of restriction enzymes and then cloned into the expression vector. The expression vector can be uniquely tagged (e.g. GST) to produce a fusion peptide ready for expression testing and utilization.

PepID allows user to adjust either peptide length or the peptide overlap as shown here. Varying the peptide length (A) and overlap (B) increases resolution of the epitope binning/scanning process to help identify new linear epitopes or even conformational epitopes.

Figure 2: PepID allows user to adjust either peptide length or the peptide overlap as shown here. Varying the peptide length (A) and overlap (B) increases resolution of the epitope binning/scanning process to help identify new linear epitopes or even conformational epitopes.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Molecular Engineering for in silico Multi-Gene Expression BioDesigns


Molecular Engineering for in silico Multi-Gene Expression BioDesigns


ATG Logo

Products & Services | ATG:biosynthetics GmbH

Introduction

ATG:biosynthetics core capabilities include high quality bioinformatics approaches for applications in drug discovery of natural product compounds, development and bio-production. Especially bioinformatics in comparative genomics and molecular genetics forms a major part of ATG activities, using proprietary software developments for detailed genomics analyses in the planning phase and realization of projects, creating the scope for broader understanding of the structural and functional constitution of genomes, individual genes and regulatory issues of gene clusters and regulatory networks of specific organisms. This allows the identification of the molecular requirements of sequences for proper and even improved function.

These all place emphasis on predictive bio-design and being able to analyze the genomes of gene source and target organisms in detail like the comparison of organism genomes in terms of ortho and paralogous pathway genes and related regulators. This constitutes the most informative sources for the discovery of new functional gene products like new enzyme specificities, for the development of new natural drug pathways in drug discovery and for the establishment of efficient high yield bio-production systems.

Epitope mapping with PepID-bioPeptides

For example in immune genomics bioinformatics for identification of potential antigens, reduction of molecular complexity and immunogenic epitopes accessible for the immune system ATG has acquired useful skills. Comparative genomics is an indispensible tool in project planning, fitting the functional realities of specific activities with protein expressing systems.

One example is use of proprietary PepID technology to perform mapping of epitopes, covering the biodiversity in pathogen bacterial and viral genomes in order to find out the most plausible antigens. In addition tANCHOR a patented protein display technology for Mammalian cells can be equipped with antigenic determinant epitopes like cancer epitopes for further analytical or therapeutic use for protein or DNA vaccines and antibody development in diagnostics and therapy. The relevant designs can be delivered by ATG to promote your R&D.

Pathway engineering and combinatorial BioDesigns with EvoMAG

The latter is realized via pathway engineering for the realization of commercial Synthetic Biology application projects. ATG’s proprietary EvoMAG (Evolution Mediated Artificial Genetics) software package was designed for in parallel processing of multiple genes and gene variant libraries from different genetic sources. This calculates by ribosomes highly accessible mRNA-structures around the translational initiation regions TIRs.

EvoMAG generates the translational initiation region with multi-target parameter improvements that impact on the general translatability of the mRNA. It is then possible to eliminate the negative impact of molecular features and motives, to allow the specific activity of the gene products like co-translational folding, and, at the level of mRNA-stability and biological half-life, to tune the number of translational events.

Resources

Click on Molecular Engineering for in silico Multi-Gene Expression BioDesigns for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


ATG bioinformatics help engineer mycoplasma bacteria for new vaccine platform


ATG bioinformatics help engineer mycoplasma bacteria for new vaccine platform


ATG Logo
MycoSync Logo

Press Release | ATG:biosynthetics GmbH

MAY 25, 2016

Merzhausen, Germany: – German-based clinical research organization ATG:biosynthetics has contributed its expertise in functional bioinformatics to a Europe-wide project that has combined gene engineering and biotechnology to design new vaccines based on the bacterium Mycoplasma pneumoniae.

ATG is a member of the MycoSynVac consortium undertaking an €8m EU-funded five-year project that was launched in May 2015 at the Centre for Genomic Regulation (CRG) in Barcelona.

The Spanish-co-ordinated project, undertaken under the EU’s Horizon 2020 (H2020) Research and Innovation program, also involves industrial and academic partners in UK, Germany, Denmark, The Netherlands, France, and Austria.

Cutting edge synthetic biology

The project combines systems biology with advanced synthetic biology methodologies to enable researchers to engineer a universal Mycoplasma bacterium chassis that will be optimized for fast and contamination-free growth.

The new chassis will be used to create vaccines targeting two highly detrimental pathogens that cause livestock animal suffering, with significant costs to the livestock industry. It is hoped it will also provide a platform for further applications, such as combating infectious lung diseases.

Using ATG peptide library

“The role of ATG:biosynthetics in this project has been of crucial importance for the success of the vaccine design,” said ATG’s CEO, Dr. Hubert S. Bernauer.

ATG’s Lab Head/Project Manager Adrien Eberlin, PhD, added, “We have had to identify new epitopes at the surface of M. hyopneumoniae, M.bovis and M.gallisepticum that will constitute new targets for the host immune system. The difficulty of this task relies on the complexity of our peptide library to handle to identify the numerous strategies that have been selected by mycoplasmas throughout evolution to escape the host immune system.”

“To fulfill this challenging mission, we have needed to combine our bioinformatic expertise with PepID technology for epitope mapping,” he added.

Overcoming mycoplasma barrier

Mycoplasmas infect animals and humans, with very few effective vaccines developed so far. Researchers have struggled to overcome the difficulty in growing most mycoplasmas in isolation from other organisms, requiring complex media that include animal serum. Thus, even where effective vaccines are available, they are hard to produce, with the process resistant to scale up and highly susceptible to viral contamination.

MycoSynVac seeks to harness extensive systems biology knowledge about M. pneumoniae and cutting-edge synthetic biology methodologies to design a universal Mycoplasma ‘chassis’ bacterium that will grow efficiently in a serum-free medium, to significantly improve production, quality, and efficiency. Resulting single- or multi-vaccine products can then be deployed in a range of animal hosts.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

About MycoSynVac

The Mycosplasma bacteria are the smallest self-replicating organisms. Their lack of cell wall make them resistant to almost all antibiotics. Infections caused by Mycoplasma in livestock result in annual multimillion losses around the world. Although there are vaccines against two species of Mycoplasma that affect pigs and poultry, no vaccines exist for those Mycoplasma species that affect not only livestock but also pets and humans.

The new H2020 EU project MycoSynVac aims to bio-engineer Mycoplasma pneumoniae into a universal chassis for vaccination by using cutting-edge synthetic biology methodologies.

“We will engineer a new bacteria to be used as a vaccine, explains Luis Serrano, director of the Centre for Genomic Regulation (CRG), who his one of the project co-ordinators. “We will remove the genes that make the bacteria pathogenic and then improve the chassis for an optimized growth in a serum-free medium. By expressing specific harmless antigens from one or more pathogens, we will be able to create targeted vector vaccines.”

“We have been working for a long time to deeply understand Mycoplasma pneumoniae and are now ready to take a step forward and use this knowledge for the benefit of society”, adds Maria Lluch, staff scientist at the CRG and scientific co-coordinator of MycoSynVac.

A second phase of this project includes targeting the development of attenuated (with the pathogen weaken but still alive) and/or inactivated vaccines (with killed pathogen) against M. hyopneumoniae, which infects pigs, and M. bovis, which infects cattle.

The project pursues an ambitious challenge that requires both technical details but also societal and ethical dimensions to be taken into account.

To effectively address these highly diverse aspects, the project consortium is composed of: research groups working on gene engineering and design of biological systems at the CRG (Barcelona, Spain), the French National Institute for Agricultural Research (Bordeaux, France), Wageningen University ( The Netherlands), and Imperial College (London, UK), along with a research group focused on bioethical aspects from University of Copenhagen (Denmark); industrial partners of MSD Animal Health (Boxmeer, The Netherlands) and ATG Biosynthetics, along with risk assessment and public engagement experts Biofaction (Vienna, Austria).

Media Contact

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on ATG bioinformatics help engineer mycoplasma bacteria for new vaccine platform for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/


Research testimonial confirms ATG’s PepID efficacy in epitope mapping


Research testimonial confirms ATG’s PepID efficacy in epitope mapping


ATG Logo

Press Release | ATG:biosynthetics GmbH

MAY 05, 2016

Merzhausen, Germany: – A testimonial from the highly respected Center for Pathophysiology, Infectiology and Immunology at Medical University of Vienna pays tribute to the effectiveness of PepID technology and libraries developed by German-based clinical research organization ATG:biosynthetics.

ATG’s peptide libraries and PepID have proved essential to the advanced epitope mapping work being carried out by researcher Dr. Joshua Tobias, working in the Center’s Institute of Specific Prophylaxis and Tropical Medicine.

Dr. Tobias has depended on ATG for support in six successive projects focusing on epitope mapping.

PepID libraries

Dr. Tobias writes:
“The PepID technology, which is offered by ATG:biosynthetics, was found very suitable for this purpose. Therefore, for almost half a year now I have purchased in several libraries of peptides prepared by ATG and based on PepID technology.”

Dr. Tobias also commended the quality of ATG’S library preparation and general service levels.

Service and solutions

“I would like to thank ATG:biosynthetics for the professional preparation of the libraries, and in particular I appreciate the provided service. ATG’s contact people are very helpful and enthusiastic in providing any necessary information regarding provided materials and also in suggesting solutions where necessary,” he says.

“Altogether, based on my experience and satisfaction, I highly recommend ATG:biosynthetics for their professionalism, services and availability,” Dr. Tobias concludes.

About ATG: biosynthetics

Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.

ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.

ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.

Media Contact

Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Email: info@atg-biosynthetics.de

Resources

Click on Research testimonial confirms ATG’s PepID efficacy in epitope mapping for more information.
Click on ATG to contact the company directly.


Supplier Information
Supplier: ATG:biosynthetics GmbH
Address: Weberstrasse 40, 79249 Merzhausen, Germany
Tel: +49 (0) 761 888 9424
Fax: +49 761 888 9425
Website: www.atg-biosynthetics.com/